 class C2-C6), including 470 C2 patients,
PEM ablation (Varithena;, BTG International Ltd, London,
UK) was compared with EVLA using the VenaCure 1470nm laser system (Angiodynamics, Waterlooville, UK).
Reï¬‚ux was eliminated in 93.5% (514 of 550) and 92.8%

(482 of 5